More recently, Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) have garnered attention among clinicians managing patients with congestive heart failure, because of the clinical trials using SGLT2i show an important reduction in mortality, morbidity, and adverse renal outcomes in diabetic and non-diabetic patients with Heart failure with reduced ejection fraction (HFrEF) [2]. Here, SLC5A2 is linked to heart failure.